Randomized Trialhigh evidence
Salovum® reduces mortality in isolated severe traumatic brain injury: a randomized phase II trial.
Brain : a journal of neurology·September 7, 2026·PMID 42705343
Why it mattersSevere traumatic brain injury carries high mortality, especially in low- and middle-income settings where effective neuroprotective therapies are lacking. A simple, inexpensive, nasogastrically administered intervention that reduces mortality could address a major unmet need in neurocritical care.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled